Q BioMed Inc. (QBIO)

OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Mar 6, 2026, 9:30 AM EST
9,900%
Market Cap 145.00
Revenue (ttm) 209.29K
Net Income (ttm) -1.91M
Shares Out 145.09M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 22,324
Open 0.0001
Previous Close 0.0001
Day's Range 0.0001 - 0.0001
52-Week Range 0.0000 - 0.0251
Beta 181.13
RSI 53.39
Earnings Date n/a

About Q BioMed

Q BioMed Inc. engages in the acquisition, development, and financing of biomedical assets. The company offers Strontium Chloride Sr-89/Metastron, a radiopharmaceutical for the treatment of metastatic cancer bone pain. It also develops various preclinical candidates comprising QBM-001 for rare pediatric non-verbal autism spectrum disorder; UTTROSIDE-B, a chemotherapeutic for liver cancer; and MAN-01, a topical eyedrops for glaucoma. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Country United States
Stock Exchange OTCMKTS
Ticker Symbol QBIO
Full Company Profile

Financial Performance

In fiscal year 2022, Q BioMed's revenue was $284,352, an increase of 45.38% compared to the previous year's $195,597. Losses were -$3.49 million, -60.03% less than in 2021.

Financial Statements

News

There is no news available yet.